Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial

PURPOSE: Alisertib is an oral Aurora A kinase inhibitor with preclinical activity in neuroblastoma. Irinotecan and temozolomide have activity in patients with advanced neuroblastoma. The goal of this phase I study was to determine the maximum tolerated dose (MTD) of alisertib with irinotecan and tem...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Clin Oncol
Hlavní autoři: DuBois, Steven G., Marachelian, Araz, Fox, Elizabeth, Kudgus, Rachel A., Reid, Joel M., Groshen, Susan, Malvar, Jemily, Bagatell, Rochelle, Wagner, Lars, Maris, John M., Hawkins, Randall, Courtier, Jesse, Lai, Hollie, Goodarzian, Fariba, Shimada, Hiroyuki, Czarnecki, Scarlett, Tsao-Wei, Denice, Matthay, Katherine K., Mosse, Yael P.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Clinical Oncology 2016
Témata:
ORIGINAL REPORTS
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4872349/
https://ncbi.nlm.nih.gov/pubmed/26884555
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2015.65.4889
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky